ArticleJournal of oral biology and craniofacial research
Effects of melatonin alone or in combination with Bio-Oss® on early osteoblastic activity: An
Article in Journal of oral biology and craniofacial research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Melatonin modulates bone metabolism and enhances osteogenic activity; however, whether these effects are maintained when combined with xenogeneic bone substitutes during early osteoblastic responses remains unclear. This study investigated the effects of melatonin alone and combined with the xenogeneic bone substitute Bio-Oss® on early osteoblastic activity Methods: Human osteoblast-like cells (SaOS-2) were allocated to four groups: control, melatonin (0.1 mM), Bio-Oss® (10 mg/mL), and melatonin plus Bio-Oss®. Three independent biological experiments were performed. Cell proliferation (Trypan blue exclusion), viability (MTT assay), and type I collagen secretion (ELISA) were assessed at 24 h, 72 h, and 7 days. Data were analyzed using the Kruskal-Wallis test followed by Dunn's post hoc test ( Results: Proliferation and viability increased over time in all groups. At 7 days, Bio-Oss®-containing groups showed significantly reduced proliferation compared with the control group ( Conclusion: Combining melatonin with Bio-Oss® did not enhance early osteoblastic activity in this
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.